Form 4: Madrigal Pharmaceuticals Director Kenneth Bate Receives Stock and Option Grants

Director Kenneth Bate of Madrigal Pharmaceuticals received restricted stock units and stock options on June 25, 2024, according to a Form 4 filing.

Summary

• Kenneth Bate, a director at Madrigal Pharmaceuticals, received a grant of 714 restricted stock units on June 25, 2024, at a price of $0.00.
• These restricted stock units will vest on June 25, 2025, contingent upon continued service with the Issuer.
• Bate also received an option to buy 1,105 shares of common stock at an exercise price of $280.04 on the same date.
• The stock options vest 100% on the first anniversary of the grant date, provided Bate continues to serve as a director.
• Following these transactions, Bate beneficially owns 1,912 shares of common stock and options for 1,105 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units is a standard practice and generally viewed favorably as it aligns the interests of the director with the company's long-term performance.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with the long-term success of Madrigal Pharmaceuticals.
• The vesting conditions incentivize continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Stock grants and options are common forms of executive compensation in the pharmaceutical industry, aligning management interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded pharmaceutical companies.
• The vesting schedules are typical, often tied to continued service to ensure alignment with company goals.
• Comparable companies like Viking Therapeutics and Intercept Pharmaceuticals also utilize stock options and restricted stock units as part of their director compensation.

Stakeholder Impact

• Shareholders may view the stock and option grants positively as they incentivize the director to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates